Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04868643
Other study ID # DIAL-DIMI-001
Secondary ID
Status Withdrawn
Phase N/A
First received
Last updated
Start date January 2023
Est. completion date August 2026

Study information

Verified date March 2024
Source Dialco Medical Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a prospective, multicenter, open label, non-randomized, cross-over study. Subjects will be enrolled in the trial for approximately 18 weeks and will use the DIMI RRT System for their dialysis treatments for all study phases, according to the schedule outlined below. The schedule will consist of four phases and the number of sessions per week will be prescribed the same throughout Phase 1 to 4.


Description:

1. Phase 1: Run-in. Duration: 2 weeks. Potential Subjects will undergo dialysis treatments 3 - 5 times per week for up to 2 weeks In-Center. Treatments will be administered by study staff during this phase. Study eligibility will be assessed for both the potential Subject and their Care Partner after completion of the run-in period. Potential subjects and Care Partners who meet all eligibility criteria will be invited to Phase 2. 2. Phase 2: In-Center Treatment. Duration: 6 weeks. Subjects will undergo dialysis treatments 3 - 5 times per week for approximately 6 weeks (for a total of 18 - 30 sessions) In-Center. Treatments will be administered by study staff. 3. Phase 3: Cross-over Period from In-Center to In-Home environment. Duration: 4 weeks. Care Partners will undergo the DIMI training, then perform dialysis treatments on Subjects 3 - 5 times per week for approximately 4 weeks (for a total of 12 - 20 sessions). Treatments will be completed In-Center under the supervision of hemodialysis nurses and at the discretion of the investigator. 4. Phase 4: In-Home Treatment. Duration: 6 weeks. Care Partners will perform dialysis treatments to the Subject 3 - 5 times per week for approximately 6 weeks (for a total of 18 - 30 sessions) in a home environment.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date August 2026
Est. primary completion date August 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Subject has provided informed consent and has signed a Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant authorization statement. 2. Subject is at least 18 years and less than 75 years of age. 3. Subject has identified an individual "Care Partner" to be trained and available as needed. Such Care Partner must be considered competent to train on the use of the device by the prescribing physician, and must commit to the trial. 4. Subject has end stage renal disease (ESRD) adequately treated by maintenance dialysis achieving a Kt/V = 1.2 and has been deemed stable for at least three months by his/her treating nephrologist. 5. Subject has a well-functioning and stable vascular access that allows a blood flow of at least 300 ml/min. 6. Subject has a documented psychosocial evaluation by a qualified social worker, treating physician or home hemodialysis nurse. 7. Subject has no childbearing potential or has a negative pregnancy test within 7 days prior to the start of the first study treatment and will be utilizing medically acceptable means of contraception during the study period. 8. Subject has a home environment to perform hemodialysis that meets the criteria of Home Use Environment (defined in Section 15.1). Exclusion Criteria: 1. Subject has dementia or lacks capacity for self-care. 2. Life expectancy less than 12 months from first study procedure. 3. Subject is unable to understand or cooperate with hemodialysis nurse and dialysis care team. 4. Subject has a documented history of non-adherence to dialysis treatment that would prevent successful completion of the study. 5. Subject has had a recent major cardiovascular adverse event within the last 3 months. 6. Subject has New York Class III or IV Congestive Heart Failure, or ejection fraction less than 30%. 7. Subject has a persistent pre-dialysis sitting systolic blood pressure less than 100 mmHg despite medical therapy. 8. Subject has symptomatic intra-dialytic hypotension requiring medical intervention in two of their last three treatments. 9. Subject has an active infection requiring antibiotics within the last 7 days. 10. Subject has fluid overload due to intractable ascites secondary to liver cirrhosis. 11. Subject has uncontrolled blood pressure (e.g. sustained/persistent pre- dialysis systolic blood pressure greater than 180 mmHg despite maximal medical therapy in two of the last three treatments). 12. Subject is intolerant to heparin. 13. Subject is seroreactive for Hepatitis B Surface Antigen. 14. Subject has an active, life-threatening, rheumatologic disease. 15. Subject has a history of adverse reactions to dialyzer membrane material. 16. Subject is participating in another investigative drug or device clinical study related to Home Hemodialysis which conflicts with the execution of this study. 17. Subject is expected to receive a kidney transplant from any donor organ in the next 6 months. 18. Subject has a life-threatening malignancy actively receiving treatment that would prevent successful completion of the study protocol. 19. Any other condition that the Investigator feels would prevent the Subject from being a suitable candidate for inclusion in the study.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
The DIMI Renal Replacement Therapy (RRT) System
To demonstrate that the safety and efficacy of the DIMI RRT remains consistent when used In-Center by trained dialysis nurses versus in an In-Home environment by trained Care Partners and Subjects.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Dialco Medical Inc.

Outcome

Type Measure Description Time frame Safety issue
Primary Delivery of the prescribed fluid volume, defined as delivered volume that is at least 90% of prescribed volume at each in-home dialysis session. The delivered volume is the total effluent volume (spent dialysate plus net ultrafiltrate) as measured by the device by means of 2 independent and calibrated electronic scales. The effluent volume is an effective means of assessing the usability of the machine in different environments and by different people, as any early interruption of treatment will result in a lower delivered volume. 6 weeks
Secondary Delivery of a standardized weekly Kt/V based on lab data. The secondary efficacy endpoint is the delivery of a standardized weekly Kt/V of greater than or equal to 2.1, that will be measured weekly. The standardized weekly Kt/V value will be computed by the Sponsor and included in the study database from laboratory data provided and recorded by the site via the Case Report Forms (CRFs). 6 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04892745 - Impact of Hemodialysis on Cutaneo-muscular Electrical Impedance
Not yet recruiting NCT04925674 - Study of HEC53856 in Patients With Subjects With End-Stage Renal Disease Receiving Dialysis. Phase 1
Active, not recruiting NCT03183245 - Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis Phase 3
Completed NCT03365635 - Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C Phase 4
Withdrawn NCT02904343 - Evaluation of Domestic Hemodialysis Machine: A Multi-center Clinical Study N/A
Withdrawn NCT01855334 - L-Arginine and Spironolactone Trial in Dialysis-Dependent ESRD Phase 4
Completed NCT01700465 - Estimating and Predicting Hemodynamic Changes During Hemodialysis N/A
Recruiting NCT01195519 - The Assessment of Quality of Life in Patients With Peritoneal Dialysis and Hemodialysis N/A
Completed NCT00737672 - GORE VIABAHN Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise AV Grafts in Hemodialysis Phase 3
Completed NCT00527774 - Effect of HCV Infection on Insulin Resistance and Malnutrition-inflammation Complex Syndrome in Regular Hemodialysis Patients N/A
Completed NCT00942253 - Exercise Training in Dialysis Patients With Restless Legs Syndrome (RLS) Phase 2
Completed NCT00224081 - DRIVE Trial (Dialysis Patients' Response to Intravenous [IV] Iron With Elevated Ferritin) Phase 4
Completed NCT00850252 - Use of a Lifeline Graft in the A-V Shunt Model Phase 1/Phase 2
Completed NCT00776750 - Influenza Vaccination in Hemodialysis Patients and Renal Transplant Recipients Phase 4
Recruiting NCT06351007 - Educational Program on Dietary Adherence and Nutritional Knowledge in Chronic Kidney Disease Patients (EPAK) N/A
Withdrawn NCT03664141 - Impact of Cannabis Oil on Nutrition in Hemodialysis Patients Study (ICON-HP Study) Phase 3
Completed NCT03909698 - Antibiotic Dosing in Patients on Intermittent Hemodialysis
Recruiting NCT03311321 - Vitamin K to Slow Progression of Cardiovascular Disease Risk in Hemodialysis Patients N/A
Recruiting NCT06098924 - HD Patients' Depression and Happiness
Recruiting NCT03419923 - Three Anticoagulation Strategies for Hemodialysis in Patients at Risk of Hemorrhage N/A